SCLX.US Scilex Holding Company

Healthcare Pharmaceuticals USA Stocks
0.6420 USD
Close of Nov 17, 2026
0.5433 16.81
Market cap
USD 4.52M
P/E
-
P/B
28.85x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is SCLX.US undervalued?

Graham number

The Graham number of Scilex Holding Company cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scilex Holding Company fundamental analysis

No fundamental analysis for Scilex Holding Company yet.

Scilex Holding Company stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scilex Holding Company

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine …

Full company profile